Literature DB >> 18795294

Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis.

Kyoung-Hwa Choi1, Wan-Hee Yoo.   

Abstract

We first report a case of patient with refractory dermatomyositis (DM) who successfully treated with tumor necrosis factor-alpha blocker, etanercept and developed necrotizing fasciitis (NF) after the use of it. NF was diagnosed early by MRI and managed with antimicrobial therapy and timely debridement of necrotic tissue with favorable outcome. We suggest that etanercept can be a useful therapeutic agent in patients with DM refractory to steroid and immunosuppressive agents and NF may occur in DM in association with etanercept therapy. We also suggest that management strategies for early diagnosis and treatment are needed for this complication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18795294     DOI: 10.1007/s00296-008-0695-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  18 in total

1.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Necrotizing fasciitis in a patient with rheumatoid arthritis.

Authors:  A McEntegart; H A Capell
Journal:  Rheumatology (Oxford)       Date:  2002-07       Impact factor: 7.580

3.  Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.

Authors:  G J D Hengstman; F H J van den Hoogen; B G M van Engelen
Journal:  Eur Neurol       Date:  2004-07-05       Impact factor: 1.710

4.  International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies.

Authors:  Chester V Oddis; Lisa G Rider; Ann M Reed; Nicolino Ruperto; Hermine I Brunner; Bhanu Koneru; Brian M Feldman; Edward H Giannini; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2005-09

Review 5.  Dermatomyositis.

Authors:  J P Callen
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

6.  Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality.

Authors:  S M Sultan; Y Ioannou; K Moss; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2002-01       Impact factor: 7.580

7.  Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis.

Authors:  A T Y Chan; V Cleeve; T J Daymond
Journal:  Postgrad Med J       Date:  2002-01       Impact factor: 2.401

8.  TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.

Authors:  L M Pachman; M R Liotta-Davis; D K Hong; T R Kinsella; E P Mendez; J M Kinder; E H Chen
Journal:  Arthritis Rheum       Date:  2000-10

9.  Expression of tumor necrosis factor-alpha in muscles of polymyositis.

Authors:  M Tateyama; I Nagano; M Yoshioka; K Chida; S Nakamura; Y Itoyama
Journal:  J Neurol Sci       Date:  1997-02-27       Impact factor: 3.181

10.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Authors:  M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

View more
  6 in total

1.  Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome.

Authors:  Paola Sabrina Buonuomo; Andrea Campana; Antonella Insalaco; Claudia Bracaglia; Manuela Pardeo; Elisabetta Cortis
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

2.  A case of cellulitis causing tissue defect during etanercept therapy.

Authors:  Dulgeroglu Deniz; Umay Ebru; Bal Ajda; Tetik Menevse Gulsum; Tatlican Semih; Cakci Aytul
Journal:  Rheumatol Int       Date:  2009-12-18       Impact factor: 2.631

3.  Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker.

Authors:  Christian Renaud; Philippe Ovetchkine; Patricia Bortolozzi; Claire Saint-Cyr; Bruce Tapiero
Journal:  Eur J Pediatr       Date:  2010-11-10       Impact factor: 3.183

4.  Necrotizing fasciitis in a patient with overlap syndrome of systemic sclerosis and systemic lupus erythematosus.

Authors:  Jong-Hwan Chong; Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2009-11-05       Impact factor: 2.631

Review 5.  Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2011-01-21       Impact factor: 6.682

Review 6.  New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review.

Authors:  Alexandra Maria Giovanna Brunasso; Werner Aberer; Cesare Massone
Journal:  ScientificWorldJournal       Date:  2014-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.